» Articles » PMID: 33461590

The Inflammatory Kinase IKKα Phosphorylates and Stabilizes C-Myc and Enhances Its Activity

Overview
Journal Mol Cancer
Publisher Biomed Central
Date 2021 Jan 19
PMID 33461590
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The IκB kinase (IKK) complex, comprising the two enzymes IKKα and IKKβ, is the main activator of the inflammatory transcription factor NF-κB, which is constitutively active in many cancers. While several connections between NF-κB signaling and the oncogene c-Myc have been shown, functional links between the signaling molecules are still poorly studied.

Methods: Molecular interactions were shown by co-immunoprecipitation and FRET microscopy. Phosphorylation of c-Myc was shown by kinases assays and its activity by improved reporter gene systems. CRISPR/Cas9-mediated gene knockout and chemical inhibition were used to block IKK activity. The turnover of c-Myc variants was determined by degradation in presence of cycloheximide and by optical pulse-chase experiments.. Immunofluorescence of mouse prostate tissue and bioinformatics of human datasets were applied to correlate IKKα- and c-Myc levels. Cell proliferation was assessed by EdU incorporation and apoptosis by flow cytometry.

Results: We show that IKKα and IKKβ bind to c-Myc and phosphorylate it at serines 67/71 within a sequence that is highly conserved. Knockout of IKKα decreased c-Myc-activity and increased its T58-phosphorylation, the target site for GSK3β, triggering polyubiquitination and degradation. c-Myc-mutants mimicking IKK-mediated S67/S71-phosphorylation exhibited slower turnover, higher cell proliferation and lower apoptosis, while the opposite was observed for non-phosphorylatable A67/A71-mutants. A significant positive correlation of c-Myc and IKKα levels was noticed in the prostate epithelium of mice and in a variety of human cancers.

Conclusions: Our data imply that IKKα phosphorylates c-Myc on serines-67/71, thereby stabilizing it, leading to increased transcriptional activity, higher proliferation and decreased apoptosis.

Citing Articles

Glioblastoma multiforme: insights into pathogenesis, key signaling pathways, and therapeutic strategies.

Pouyan A, Ghorbanlo M, Eslami M, Jahanshahi M, Ziaei E, Salami A Mol Cancer. 2025; 24(1):58.

PMID: 40011944 PMC: 11863469. DOI: 10.1186/s12943-025-02267-0.


Anti-Cancer Effect of Sulforaphane in Human Pancreatic Cancer Cells Mia PaCa-2.

Park M, Kim Y Cancer Rep (Hoboken). 2024; 7(12):e70074.

PMID: 39632551 PMC: 11617590. DOI: 10.1002/cnr2.70074.


Nuclear versus cytoplasmic IKKα signaling in keratinocytes leads to opposite skin phenotypes and inflammatory responses, and a different predisposition to cancer.

Garcia-Garcia V, Alameda J, Fernandez-Acenero M, Navarro M, Garcia-Escudero R, Page A Oncogene. 2024; 44(3):165-178.

PMID: 39511409 PMC: 11725495. DOI: 10.1038/s41388-024-03203-0.


Bioinformatic Analysis of Complex Genes Expression in Selected Gastrointestinal Cancers.

Zebrowska-Nawrocka M, Szmajda-Krygier D, Krygier A, Jelen A, Balcerczak E Int J Mol Sci. 2024; 25(18).

PMID: 39337357 PMC: 11432643. DOI: 10.3390/ijms25189868.


Pharmacological effects and the related mechanism of scutellarin on inflammation-related diseases: a review.

Zhou Y, Gu C, Zhu Y, Zhu Y, Chen Y, Shi L Front Pharmacol. 2024; 15:1463140.

PMID: 39188946 PMC: 11345237. DOI: 10.3389/fphar.2024.1463140.


References
1.
Chen H, Liu H, Qing G . Targeting oncogenic Myc as a strategy for cancer treatment. Signal Transduct Target Ther. 2018; 3:5. PMC: 5837124. DOI: 10.1038/s41392-018-0008-7. View

2.
Rebello R, Pearson R, Hannan R, Furic L . Therapeutic Approaches Targeting MYC-Driven Prostate Cancer. Genes (Basel). 2017; 8(2). PMC: 5333060. DOI: 10.3390/genes8020071. View

3.
Gilmore T . Introduction to NF-kappaB: players, pathways, perspectives. Oncogene. 2006; 25(51):6680-4. DOI: 10.1038/sj.onc.1209954. View

4.
Alameda J, Gaspar M, Ramirez A, Navarro M, Page A, Suarez-Cabrera C . Correction: Deciphering the role of nuclear and cytoplasmic IKKα in skin cancer. Oncotarget. 2017; 8(32):53886. PMC: 5581157. DOI: 10.18632/oncotarget.20001. View

5.
Wu R, Qin J, Hashimoto Y, Wong J, Xu J, Tsai S . Regulation of SRC-3 (pCIP/ACTR/AIB-1/RAC-3/TRAM-1) Coactivator activity by I kappa B kinase. Mol Cell Biol. 2002; 22(10):3549-61. PMC: 133790. DOI: 10.1128/MCB.22.10.3549-3561.2002. View